EUVIMEDEUVIMED entdecken
Crossref

Plasma expression of antisense LncRNAs RBM5-AS1, VPS9D1-AS1 and STEAP3-AS1 as novel biomarkers for colorectal cancer diagnosis

Mohammadreza Karbalaei Hashemiyan, Reza Manouchehri Ardekani, Mohsen Razavizade, Ali Rafat, Mohsen Hemmati-Dinarvand

Molecular Biology Reports · 2025

DOI: 10.1007/s11033-025-10696-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Mohammadreza Karbalaei Hashemiyan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Hauptthemen laut MEDLINE: Colorectal Neoplasms, RNA, Long Noncoding, Biomarkers, Tumor, RNA-Binding Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Kashan University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Colorectal cancer (CRC) remains a significant cause of cancer-related mortality globally, primarily due to late-stage diagnoses. This study investigates the expression levels of antisense long non-coding RNAs (lncRNAs) RBM5-AS1, STEAP3-AS1, and VPS9D1-AS1 in both tissue and plasma samples from CRC patients to evaluate their potential as diagnostic biomarkers. Selection of these lncRNAs was based on prior studies indicating their dysregulation in CRC and their role in the Wnt/β-catenin signaling pathway, which modulates cell growth, apoptosis, and differentiation. MATERIALS AND METHODS: This experimental study included 40 plasma samples and 10 tissue samples from CRC patients, alongside an equal number of samples from healthy controls. The expression levels of the lncRNAs and β-catenin were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic performance of these lncRNAs was evaluated through receiver operating characteristic (ROC) curve analysis on Plasma samples, which also facilitated the determination of optimal cutoff values. RESULTS: The expression of the β-catenin gene was significantly elevated in CRC tissues (6.78-fold increase, p = 0.02) and plasma samples (4.79-fold increase, p < 0.001) compared to controls. Likewise, the expression levels of the lncRNAs were significantly higher in both CRC tissues and plasma samples relative to healthy subjects (p < 0.001). ROC curve analysis revealed robust predictive capabilities for the plasma expression of these lncRNAs, with area under the curve (AUC) values of 0.82 for STEAP3-AS1, 0.94 for VPS9D1-AS1, and 0.83 for RBM5-AS1. CONCLUSION: The findings indicate that the expression levels of β-catenin and lncRNAs STEAP3-AS1, VPS9D1-AS1, and RBM5-AS1 are significantly higher in both tissue and plasma samples from CRC patients compared to healthy individuals. Consequently, these lncRNAs may serve as promising biomarkers for CRC diagnosis. However, further studies are needed to validate these findings and explore additional applications.td.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsRNA, Long NoncodingBiomarkers, TumorRNA-Binding ProteinsHumansMaleFemaleMiddle AgedGene Expression Regulation, NeoplasticAgedbeta CateninROC CurveWnt Signaling PathwayCase-Control StudiesDNA-Binding ProteinsCell Cycle ProteinsTumor Suppressor Proteins

Stichwörter der Autor:innen

BiomarkerColorectal cancerLncRNAsWnt/β-catenin signaling

Substanzen

RNA, Long NoncodingBiomarkers, Tumorbeta CateninRNA-Binding ProteinsRBM5 protein, humanDNA-Binding ProteinsCell Cycle ProteinsTumor Suppressor Proteins

Autor:innen und Institutionen

  • Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
  • Department of Clinical Biochemistry, Kashan University of Medical Sciences, Kashan, Iran.
  • Autoimmune Diseases Research Center, Department of hematology and oncology, Beheshti Hospital, Kashan, Iran.
  • Gastroenterology Department, Beheshti Hospital, Kashan University of Medical Sciences, Kashan, Iran.
  • Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
  • Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Mohsen_h43@yahoo.com.

Förderung

  • Kashan University of Medical Sciences

Zitieren

APA

Karbalaei Hashemiyan, M., Manouchehri Ardekani, R., Razavizade, M., Rafat, A., & Hemmati-Dinarvand, M. (2025). Plasma expression of antisense LncRNAs RBM5-AS1, VPS9D1-AS1 and STEAP3-AS1 as novel biomarkers for colorectal cancer diagnosis. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10696-9

Vancouver

Karbalaei Hashemiyan M, Manouchehri Ardekani R, Razavizade M, Rafat A, Hemmati-Dinarvand M. Plasma expression of antisense LncRNAs RBM5-AS1, VPS9D1-AS1 and STEAP3-AS1 as novel biomarkers for colorectal cancer diagnosis. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10696-9

BibTeX
@article{KarbalaeiHashemiyan2025,
  author = {Karbalaei Hashemiyan, Mohammadreza and Manouchehri Ardekani, Reza and Razavizade, Mohsen and Rafat, Ali and Hemmati-Dinarvand, Mohsen},
  title = {Plasma expression of antisense LncRNAs RBM5-AS1, VPS9D1-AS1 and STEAP3-AS1 as novel biomarkers for colorectal cancer diagnosis},
  journal = {Molecular Biology Reports},
  year = {2025},
  doi = {10.1007/s11033-025-10696-9}
}
Kostenlos starten →